Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products

Anticipates projected pro forma annual net revenue of between $80 and $90 million Company expects to reduce senior debt by $34 million Company files for voluntary pre-arranged plan of reorganization with support of majority in dollar amount of debt h... Biopharmaceuticals, Acquisitions Egalet, Iroko Pharmaceuticals, SoluMatrix, VIVLODEX, TIVORBEX, ZORVOLEX, INDOCIN
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news